Icon Plc is a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries
The company specializes in offering a comprehensive range of services that encompass a wide array of phases in the drug development process, from early-stage research and clinical trials to regulatory submissions and post-market support. With a focus on advancing healthcare innovations, Icon collaborates closely with its clients to optimize their product development strategies, improve operational efficiency, and accelerate the path to market for new therapeutic products. Their expertise encompasses various therapeutic areas, providing tailored solutions that address the specific needs of each client.
ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.
ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET.
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
ICON plc, (NASDAQICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted earnings per share* is expected to be in the range of $13.00 - $15.00, which is flat over the expected full year 2024 adjusted earnings per share guidance midpoint.
ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies.
ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.
ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024.
ICON plc (NASDAQICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO).
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty valuations ever.
ICON plc, (NASDAQICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith continues its investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz continues its investigation of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) investors concerning the Company’s possible violations of federal securities laws.
Elliott Investment Management was busy in the third quarter. According to a new 13-F filing with the SEC, the activist made several portfolio moves, with multiple new positions focused around travel and lodging.
The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“Icon” or the “Company”) (NASDAQICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
ICON plc, (NASDAQICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT.
